Company

Dynavax Technologies Corporation

Headquarters: EmeryVille, CA, United States

Employees: 311

CEO: Mr. Ryan Spencer

NASDAQ: DVAX -5.49%

Market Cap

$1.91 Billion

USD as of Jan. 1, 2024

Market Cap History

Dynavax Technologies Corporation market capitalization over time

Evolution of Dynavax Technologies Corporation market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Dynavax Technologies Corporation

Detailed Description

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Dynavax Technologies Corporation has the following listings and related stock indices.


Stock: NASDAQ: DVAX wb_incandescent

Stock: FSX: DYF1 wb_incandescent

Details

Headquarters:

2100 Powell Street

Suite 900

EmeryVille, CA 94608

United States

Phone: 510 848 5100

Fax: 510 848 1327